• If you are wondering whether BioNTech's current share price lines up with its underlying value, this article will walk you through the key pieces that matter most.
• BioNTech shares last closed at US$118.0, with returns of 8.3% over 7 days, 24.8% over 30 days and 22.0% year to date, while the 1 year, 3 year and 5 year returns were a 1.5% decline, 16.0% decline and 2.6% respectively.
• Recent news flow around BioNTech has focused on its position in the pharmaceuticals and biotech space, including continued attention on its mRNA platform and pipeline partnerships. These developments give useful context for the recent share price movements and set up the question of whether the market is pricing the company fairly right now.
• On Simply Wall St's valuation checks, BioNTech currently scores 3 out of 6. We will look at what that means across different valuation methods, then finish by highlighting a way to tie those numbers back to the wider story behind the stock.

Approach 1: BioNTech Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash BioNTech is expected to generate in the future and then discounts those cash flows back to today to estimate what the whole business could be worth right now.

For BioNTech, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in €. The latest twelve month free cash flow is a loss of about €806.3m. Analyst estimates and extrapolated figures then project free cash flow moving through a period where it stays negative for several years, before reaching about €438.96m in 2030 and continuing to grow in the years after, according to Simply Wall St’s projections.

When all those future cash flows are discounted back, the model suggests an intrinsic value of about $176.56 per share. Compared with the recent share price of $118.0, this implies the stock is 33.2% undervalued based on this DCF snapshot.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioNTech is undervalued by 33.2%. Track this in your watchlist or portfolio, or discover 886 more undervalued stocks based on cash flows.

Approach 2: BioNTech Price vs Sales

For companies where earnings are uneven or volatile, the P/S ratio is often a useful cross check because it compares the share price with the revenue the business generates, rather than profits that can swing around from year to year.

Investors usually expect a higher or lower P/S depending on what they think about a company’s future growth and risk. Higher growth or lower perceived risk can justify paying a higher multiple, while slower growth or higher risk typically point to a lower one as a reasonable range.

BioNTech currently trades on a P/S of 7.91x. That sits below the broader Biotechs industry average of 11.90x and above the peer group average of 5.36x. Simply Wall St also calculates a proprietary Fair Ratio of 6.15x, which is intended to capture what a reasonable P/S might be given BioNTech’s earnings growth profile, margins, size, industry and risk factors.

This Fair Ratio can be more informative than a simple peer or industry comparison because it adjusts for company specific characteristics rather than assuming all Biotech names deserve similar multiples. Compared with the current 7.91x, the Fair Ratio of 6.15x suggests that BioNTech is trading at a richer level than this model would indicate.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1424 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your BioNTech Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which simply means writing the story you believe about a company and linking that story to your assumptions for fair value, future revenue, earnings and margins.

On Simply Wall St’s Community page, Narratives let you turn your view of BioNTech into a clear forecast and a fair value estimate, then compare that fair value to the current share price to help you decide whether you see the stock as an opportunity or something to avoid right now.

Because Narratives on the platform update automatically when new information arrives, such as news or earnings, your story and valuation can stay aligned with the latest data without you rebuilding your whole model each time.

For example, one BioNTech Narrative might assume relatively cautious revenue, modest margins and a fair value close to the current US$118.0 price. Another might assume stronger long term mRNA uptake, higher margins and a fair value closer to the DCF estimate of about US$176.56 per share, which could lead to very different conclusions about whether the shares look attractive today.

Do you think there's more to the story for BioNTech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.